JPH0424331B2 - - Google Patents
Info
- Publication number
- JPH0424331B2 JPH0424331B2 JP60293195A JP29319585A JPH0424331B2 JP H0424331 B2 JPH0424331 B2 JP H0424331B2 JP 60293195 A JP60293195 A JP 60293195A JP 29319585 A JP29319585 A JP 29319585A JP H0424331 B2 JPH0424331 B2 JP H0424331B2
- Authority
- JP
- Japan
- Prior art keywords
- plasminogen
- solubility
- preparation
- present
- added
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 102000013566 Plasminogen Human genes 0.000 claims description 22
- 108010051456 Plasminogen Proteins 0.000 claims description 22
- 238000002360 preparation method Methods 0.000 claims description 13
- 239000000843 powder Substances 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 150000005846 sugar alcohols Chemical class 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 238000000034 method Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 4
- 229940012957 plasmin Drugs 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 2
- 239000003527 fibrinolytic agent Substances 0.000 description 2
- 230000003480 fibrinolytic effect Effects 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical group NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000001470 plasma protein fractionation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP60293195A JPS62153224A (ja) | 1985-12-27 | 1985-12-27 | プラスミノゲン製剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP60293195A JPS62153224A (ja) | 1985-12-27 | 1985-12-27 | プラスミノゲン製剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS62153224A JPS62153224A (ja) | 1987-07-08 |
| JPH0424331B2 true JPH0424331B2 (de) | 1992-04-24 |
Family
ID=17791645
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP60293195A Granted JPS62153224A (ja) | 1985-12-27 | 1985-12-27 | プラスミノゲン製剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS62153224A (de) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06211691A (ja) * | 1993-01-11 | 1994-08-02 | Green Cross Corp:The | プラスミノゲン乾燥製剤 |
| TWI705822B (zh) | 2014-12-19 | 2020-10-01 | 美商波麥堤克生物治療股份有限公司 | 包含纖維蛋白溶酶原之醫藥組合物及其用途 |
| JP2019500422A (ja) | 2015-12-18 | 2019-01-10 | タレンゲン インターナショナル リミティッドＴａｌｅｎｇｅｎ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｌｉｍｉｔｅｄ | 急性及び慢性血栓を予防または治療することに用いる方法 |
| CN110366425A (zh) | 2016-12-15 | 2019-10-22 | 泰伦基国际有限公司 | 一种预防动脉粥样硬化及其并发症的方法 |
| CA3047181A1 (en) | 2016-12-15 | 2018-06-21 | Talengen International Limited | Method and drug for preventing and treating obesity |
| WO2018107707A1 (zh) | 2016-12-15 | 2018-06-21 | 深圳瑞健生命科学研究院有限公司 | 一种改善心脏病变的方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57193418A (en) * | 1981-05-14 | 1982-11-27 | Behringwerke Ag | Manufacture of plasminogen |
-
1985
- 1985-12-27 JP JP60293195A patent/JPS62153224A/ja active Granted
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57193418A (en) * | 1981-05-14 | 1982-11-27 | Behringwerke Ag | Manufacture of plasminogen |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS62153224A (ja) | 1987-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0444692B1 (de) | Thrombin-Zusammensetzung zur oralen Verabreichung | |
| US10898553B2 (en) | Pharmaceutical composition comprising plasminogen and uses thereof | |
| FI85335B (fi) | Foerfarande foer framstaellning av lyofiliserad, farmaceutisk vaevnadsplasminogenaktivator(t-pa)-komposition. | |
| JP5253501B2 (ja) | 安定化トロンビン組成物 | |
| JP3530300B2 (ja) | 安定なトランスグルタミナーゼ製剤およびそれらを製造する方法 | |
| CA1297008C (en) | Aqueous parenteral solution of tissue-plasminogen activator | |
| CA1340270C (en) | Thrombolytic composition and a process for production thereof | |
| JP3143470B2 (ja) | ポリペプチド含有の皮下または筋肉内投与用医薬組成物 | |
| JPS60188328A (ja) | インターフエロン投与用ビヒクル | |
| JPH07173076A (ja) | 安定化されたヒト組織プラスミノゲン活性化因子組成物の調製法 | |
| JPS6236502B2 (de) | ||
| JP2636499B2 (ja) | プラスミノーゲン活性化因子蛋白の薬学的組成物 | |
| JPH0424331B2 (de) | ||
| JPH06247872A (ja) | 高濃度ｔｃｆ製剤 | |
| JP2715104B2 (ja) | トロンビン乾燥製剤 | |
| JPS61126014A (ja) | 経鼻投与用水性液剤 | |
| CA2046598C (en) | T-pa solubilisation | |
| JPH0296536A (ja) | プラスミノゲン乾燥製剤 | |
| JPS62234030A (ja) | ｔＰＡ医薬組成物 | |
| JPH0369332B2 (de) | ||
| JPH0383931A (ja) | 低刺激性ｇｒｆ経鼻投与製剤 | |
| JPS59139323A (ja) | ウロキナ−ゼ乾燥製剤 | |
| JP4025394B2 (ja) | 組織プラスミノーゲン活性化因子医薬組成物 | |
| JP2717638B2 (ja) | 人血液凝固第ｉｘ因子含有製剤 | |
| RU2218934C2 (ru) | Препарат интерферона |